Biotech RadarJobs updated

COMPANY

Q32 Bio Inc.

HQ: Waltham, MA source · q32bio.com ↗ · New England

Clinical Phase 2

Keywords: autoimmune diseases immunology alopecia areata inflammatory diseases Atopic Dermatitis Safety Issues ADX-914 bempikibart (ADX-914)

Location: Waltham, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$65.5MRaised (2 yrs)3Trials (company is sponsor)

Timeline

  1. Raise Private placement: $55M (total, as published), announced May 27, 2026. Source: SEC filing. source ↗
  2. Raise Follow-on offering — Registered direct: $10.5M (total, as published), announced Feb 17, 2026. Source: SEC filing. source ↗
  3. Trial start 2: A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) source ↗
  4. Trial start Phase 2: Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) source ↗
  5. Trial start Phase 1: Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers source ↗

Funding

Raised: $65.5M. Last 2 years.

Clinical trials (lead sponsor) 3

RecordTitlePhaseStatusStartPrimary completion
NCT06018428A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)2Active, not recruitingSep 12, 20232026-06 (estimated)
NCT05509023Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)Phase 2Active, not recruitingSep 30, 20222024-12 (estimated)
NCT04485481Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult VolunteersPhase 1CompletedSep 8, 2020Jan 12, 2022 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback